Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Opko Health Keeps Getting Support From CEO Phillip Frost

Opko Health, CEO Phillip Frost: CEO and Chairman of Opko Health Inc. (NYSE:OPK) Phillip Frost purchased 19,000 shares of common stock earlier this week, in a series of transactions. Stock prices rose approximately 1.7% over the course of the day (Tuesday), with Frost making 15 different purchases at prices ranging from $9.46 to $9.63 per share.

Opko Health Inc. (NYSE:OPK)

The securities are held indirectly through Frost Gamma Investments Trust, of which Phillip Frost is the trustee. Total holdings now amount to 136,772,259 shares, or roughly $1.27 billion. Additionally, the Frost Group, of which Frost Gamma Investments Trust is a principal member, holds 15,490,546 shares of Opko Health directly. Hedge funds of the likes of Millennium Management, Highbridge Capital Management and Citadel Investment Group also hold large positions in the company.

Frost has been purchasing Opko stock continuously over the past few months, with large acquisitions being filled almost every week. With a reputation for investing heavily in firms he leads, and making a profit from their future sale, the acquisition of shares by Frost is motivating investors to put their money in Opko. Shareholders seem to trust this CEO, who has invested approximately 40% of his personal fortune in the pharmaceutical development and diagnostics companies.

The regular purchase of company stock began in 2007, when Frost became CEO of Opko Health. Share prices have been rising ever since, reaching a 52-week high of $10.31 on Oct. 7 2013. Opko is currently trading at 37 times its trailing sales, which means the stock entails a huge price premium relative to the industry average.

Disclosure: Pablo Erbar holds no position in any stocks mentioned

Recommended Reading:

Is Guggenheim’s Randall Barnes Rescuing Its Stock Price?

Heavy Insider Buying Activity at Aircastle

Cascade Microtech Sees One Insider Buy

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!